These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

728 related items for PubMed ID: 18768302

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand.
    Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V.
    Int J Infect Dis; 2007 Sep; 11(5):402-6. PubMed ID: 17291803
    [Abstract] [Full Text] [Related]

  • 4. Prevalence and antibiotic susceptibility of Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae in Estonian intensive care units in comparison with European data.
    Lõivukene K, Sepp E, Adamson V, Mitt P, Kallandi U, Otter K, Naaber P.
    Scand J Infect Dis; 2006 Sep; 38(11-12):1001-8. PubMed ID: 17148068
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E, 309 Study Group.
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [Abstract] [Full Text] [Related]

  • 7. Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series.
    Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A.
    Respir Med; 2009 May; 103(5):707-13. PubMed ID: 19118994
    [Abstract] [Full Text] [Related]

  • 8. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?
    Falagas ME, Bliziotis IA.
    Int J Antimicrob Agents; 2007 Jun; 29(6):630-6. PubMed ID: 17306965
    [Abstract] [Full Text] [Related]

  • 9. Multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii infections among hospitalized patients: risk factors and outcomes.
    Shanthi M, Sekar U.
    J Assoc Physicians India; 2009 Sep; 57():636, 638-40, 645. PubMed ID: 20214000
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Surveillance of antimicrobial susceptibility among bacterial isolates from intensive care unit patients of a tertiary-care university hospital in Iran: 2006-2009.
    Mohammadtaheri Z, Pourpaki M, Mohammadi F, Namdar R, Masjedi MR.
    Chemotherapy; 2010 Sep; 56(6):478-84. PubMed ID: 21099220
    [Abstract] [Full Text] [Related]

  • 13. Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.
    McCracken M, Mataseje LF, Loo V, Walkty A, Adam HJ, Hoban DJ, Zhanel GG, Mulvey MR, Canadian Antimicrobial Resistance Alliance (CARA).
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):335-41. PubMed ID: 21353962
    [Abstract] [Full Text] [Related]

  • 14. [Evolution of susceptibility to antibiotics of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumanii, in a University Hospital Center of Beirut between 2005 and 2009].
    Hamouche E, Sarkis DK.
    Pathol Biol (Paris); 2012 Jun; 60(3):e15-20. PubMed ID: 21719212
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF, Bulitta J, Lipman J, Kirkpatrick CM.
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [Abstract] [Full Text] [Related]

  • 17. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.
    Kwa AL, Loh C, Low JG, Kurup A, Tam VH.
    Clin Infect Dis; 2005 Sep 01; 41(5):754-7. PubMed ID: 16080101
    [Abstract] [Full Text] [Related]

  • 18. Treatment options for multidrug-resistant nonfermenters.
    Briceño DF, Quinn JP, Villegas MV.
    Expert Rev Anti Infect Ther; 2010 Mar 01; 8(3):303-15. PubMed ID: 20192684
    [Abstract] [Full Text] [Related]

  • 19. Mutant prevention concentrations of colistin used in combination with other antimicrobial agents against Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa clinical isolates.
    Choi MJ, Park YK, Peck KR, Ko KS.
    Int J Antimicrob Agents; 2014 Nov 01; 44(5):475-6. PubMed ID: 25443890
    [No Abstract] [Full Text] [Related]

  • 20. Emergence of concurrent infections with colistin-resistant ESBL-positive Klebsiella pneumoniae and OXA-23-producing Acinetobacter baumannii sensitive to colistin only in a Romanian cardiac intensive care unit.
    Timofte D, Dan M, Maciuca IE, Ciucu L, Dabija ER, Guguianu E, Panzaru CV.
    Eur J Clin Microbiol Infect Dis; 2015 Oct 01; 34(10):2069-74. PubMed ID: 26239064
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.